In clinical practice, several EGFR inhibitors are available to head and neck tumor patients, which are either monoclonal antibodies (cetuximab and panitumumab) or small molecule tyrosine kinase inhibitors (erlotinib, gefitinib, lapatinib, afatinib) [8]. Here, EGFR is linked to head and neck neoplasm.